Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Amylx Pharmaceuticals Inc (AMLX) vs Motorola Solutions Inc (MSI) Price & Performance

Amylx Pharmaceuticals IncTrade
Motorola Solutions IncTrade

Price performance (Past 24H)

Key statistics

Amylx Pharmaceuticals Inc vs Motorola Solutions Inc — how do they compare? Amylx Pharmaceuticals Inc trades at $23.65 (market cap $2.53B), while Motorola Solutions Inc trades at $466.86 (market cap $76.45B). The key difference: Motorola Solutions Inc is far larger — about 30.2× Amylx Pharmaceuticals Inc's market cap, and Motorola Solutions Inc pays a 1.05% dividend while Amylx Pharmaceuticals Inc pays none. Which is the better fit depends on your goals.

AMLXMSI
Market Cap
$2.53B$76.45B
Sector
HealthTechnology
52-Week High
$24.19$490.30
52-Week Low
$7.82$363.83
Enterprise Value
$2.28B$85.36B
Dividend Yield
1.05%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Amylx Pharmaceuticals Inc

AMLX trades at $22.82, down 5.66% on the day, with a bullish technical signal from moving averages and key support at $22. The company reported a net loss of -$144.74M for 2025, with negative ROE and ROA, but holds a $250.8M cash runway into 2028. The pivotal Phase 3 LUCIDITY trial for avexitide is set for a late August/early September 2026 readout, a key near-term catalyst.

Analyst consensus is strongly bullish with a $30.00 price target, though recent earnings misses and negative cash flow from operations in 2026 pose risks. The stock's outlook hinges on successful clinical trial results and the subsequent regulatory pathway for its lead endocrine asset.

Motorola Solutions Inc

Motorola Solutions (MSI) trades at $467.55, down 1.38% on the day, yet maintains a strong bullish technical trend with moving averages signaling buy. The company reported robust Q2 2026 results, beating EPS estimates with $4.41 versus $3.85 expected, and raised full-year guidance amid record backlog of $15.6 billion. Revenue grew 13% year-over-year, driven by demand in public safety communications and software services. Valuation ratios remain elevated, with a P/E of 36.84 and P/S of 6.42, reflecting premium pricing for its growth trajectory.

Outlook is positive with analyst consensus price target of $533.80 implying 14% upside, supported by strong fundamentals and institutional accumulation. Key risks include execution challenges to meet raised guidance, high valuation sensitivity to earnings misses, and macroeconomic pressures on public sector spending. The stock's current level near pivot point resistance at $471 requires monitoring for breakout confirmation.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About Amylx Pharmaceuticals Inc

Amylyx Pharmaceuticals is a biopharmaceutical firm focused on developing therapies for rare diseases. Its pipeline includes treatments for conditions like post-bariatric hypoglycemia and congenital hyperinsulinism.

Read more on AMLX

About Motorola Solutions Inc

Motorola Solutions, Inc. is a data communications and telecommunications equipment provider. The Company develops data capture, wireless, infrastructure, bar code scanning, two-way radios, and wireless broadband networks. Motorola also produces public safety and government products, voice and data communications products and systems, and wireless LAN securities.

Read more on MSI